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Introduction {#sec1}
============

The phenotypic and genetic changes that occur during tumorigenesis alter the set of genes upon which cells are dependent. The best known example of this phenomenon of "genetic dependency" is oncogene addiction where tumor cells become dependent upon the activity of a single oncogene, which when inhibited leads to cancer cell death. Alternatively, tumor cells can become addicted to the activity of genes other than oncogenes, effects known as non-oncogene addictions ([@bib47]), induced essential effects ([@bib67]), or synthetic lethal interactions ([@bib37]). From a clinical perspective, identifying genetic dependencies in tumor cells could illuminate vulnerabilities that might be translated into therapeutic approaches to treat the disease. Examples of this approach include the development of drugs that target oncogene addiction effects, such as imatinib in the case of *ABL* addiction, and therapeutic approaches that exploit synthetic lethal effects, such as PARP inhibitors for *BRCA*-deficient cancers ([@bib46]).

A number of groups have used high-throughput screening approaches such as RNAi or small molecule sensitivity screens to systematically identify genetic dependencies in tumor cell lines ([@bib4], [@bib10], [@bib17], [@bib26], [@bib40]). A particular focus has been in dissecting genetic dependencies that involve kinases ([@bib10], [@bib30]), as these enzymes play key roles in a number of oncogenic processes ([@bib29]) and are pharmacologically tractable ([@bib60], [@bib72], [@bib75]). Previously, we used high-throughput short interfering (si)RNA screening to identify the kinase dependencies in a panel of 20 breast cancer derived cell lines ([@bib10]). Here, we describe as a resource an expansion of this approach, namely parallel siRNA screens targeting 714 genes in 117 genetically and histologically diverse tumor cell lines. Building on our previous work ([@bib10]), we extend our analytical approach to describe how this data set may be used as a hypothesis-generating tool for identifying candidate therapeutic targets associated with specific tumor histotypes or mutations in cancer driver genes. We also illustrate how, by integrating this functional data with orthogonal data sources such as protein-protein interaction data sets, these genetic dependencies might be dissected mechanistically.

Results {#sec2}
=======

Kinase Genetic Dependencies Identified by Parallel siRNA Screens {#sec2.1}
----------------------------------------------------------------

We screened a panel of 136 tumor cell lines in triplicate in a plate-arrayed format using an siRNA library designed to target 714 genes (see [Experimental Procedures](#sec4){ref-type="sec"} and [Figure 1](#fig1){ref-type="fig"}A). The genes targeted with this library included 500 protein kinases ([@bib49]), with the remaining targets comprising metabolic kinases (e.g., ATP-dependent 6-phosphofructokinases), lipid kinases (e.g., PIK3C2A), as well as proteins that lack kinase activity, but directly impact kinase signaling (e.g., the cyclin dependent kinase inhibitor CDKN1C). Cells were reverse transfected with siRNA and then cultured until cells reached 70% confluency (on average 4-7 days), at which point cell viability was assessed using the CellTiter-Glo assay. Following data processing and the application of quality control filters to ensure the reproducibility and high dynamic range of each screen (see [Supplemental Information](#app3){ref-type="sec"}; [Figure 1](#fig1){ref-type="fig"}A; [Table S1](#mmc2){ref-type="supplementary-material"}A), we retained 117 high quality screens for further analysis. The resulting resource ([Table S1](#mmc2){ref-type="supplementary-material"}B) features tumor cell line models from ten different cancer types (breast, ovarian, lung, osteosarcoma, esophageal, pancreatic, head, and neck, cervical, CNS, and endometrioid; [Figure 1](#fig1){ref-type="fig"}B), and includes data for 69 lines not profiled in prior large-scale RNAi screens ([@bib10], [@bib17], [@bib40]).

To allow data to be compared between different cell lines, the viability data from each screen were standardized by the use of a robust *Z* score statistic ([Table S1](#mmc2){ref-type="supplementary-material"}B). We considered candidate kinase genetic dependencies (KGDs) in the data set as those where the siRNA elicited *Z* \< −2 effects. 76% of the kinases profiled in the screening library represented KGDs in at least one tumor cell model. Additionally, 53% and 26% represented KGDs in ≥5 and ≥10 cell lines, respectively ([Figure 1](#fig1){ref-type="fig"}C and [Table S1](#mmc2){ref-type="supplementary-material"}C). On average, each tumor cell line model exhibited 51 KGDs. A set of six kinase-coding genes (*PLK1*, *AURKA*, *WEE1*, *CHEK1, CDK11A*, and *GUCY2D*) represented KGDs in \>70% of the cell lines screened and four of these (*PLK1*, *AURKA*, *WEE1*, and *CHEK1*) are known to be involved in the mitotic cell-cycle -checkpoint.

Candidate KGDs Associated with Tumor Histotypes {#sec2.2}
-----------------------------------------------

Using average linkage hierarchical clustering to cluster the siRNA *Z* score data ([Figure 1](#fig1){ref-type="fig"}D), we found that tumor cell lines frequently clustered according to tumor histotype. For example, the majority of ovarian cancer cell lines formed a single cluster, as did those models derived from osteosarcomas ([Figure 1](#fig1){ref-type="fig"}D). Using median permutation (MP) tests on the *Z* score data, we found 151 KGDs associated with specific histotypes at a false discovery rate (FDR) of 0.1 ([Table S1](#mmc2){ref-type="supplementary-material"}D). As expected, the number of KGDs associated with each histotype was correlated with the number of cell lines screened for that histotype (Spearman's rho = 0.82), reflecting the increased statistical power resulting from a larger sample size. In breast cancer models, we found an increased requirement for *ERBB3* and *PIK3CA*, members of the ERBB2 and PI3-kinase signaling pathways that are frequently dysregulated in this cancer histology ([@bib51]). In contrast, models of osteosarcoma were more reliant upon genes involved in "skeletal system morphogenesis", including *PDGFRA*, *ACVR2B*, *TGFBR2*, *DLG1*, *FGFR1*, and *FGFR2* ([@bib64]) (Gene Ontology enrichment p \< 0.001 after correcting for multiple hypothesis testing, [@bib7]; [Figures 2](#fig2){ref-type="fig"}A and 2B). The *FGFR1* and *FGFR2* KGDs suggested that osteosarcoma models might be especially sensitive to small molecule FGFR inhibitors. Testing a set of 58 tumor cell lines for FGFR inhibitor sensitivity, we found AZD4547 ([@bib28]) and PD173074 ([@bib2]) to be more selective for osteosarcoma models (AZD4547, p = 7.6 × 10^−3^, PD173074 p = 3.9 × 10^−2^; [Figures 2](#fig2){ref-type="fig"}C and 2D; [Table S1](#mmc2){ref-type="supplementary-material"}E) and to have minimal effects in two non-tumor epithelial models ([Figure S1](#mmc1){ref-type="supplementary-material"}). This osteosarcoma selective effect was independent of *FGFR1* or *FGFR2* amplification status and was also apparent when *FGFR1* or *FGFR2* amplified tumor cell lines were excluded from the analysis (AZD4572, p = 7.2 × 10^−3^ and PD173074, p = 4.3 × 10^−2^; [Figures 2](#fig2){ref-type="fig"}C and 2D). Furthermore, the osteosarcoma selective nature of PD173074 was confirmed by a reanalysis of PD173074 sensitivity data derived from 660 tumor cell lines ([@bib26]) ([Figure 2](#fig2){ref-type="fig"}E; p = 1.4 × 10^−3^). Taken together, these results suggested that FGFR inhibitors might show some utility in osteosarcoma, but that factors in addition to *FGFR1* and *FGFR2* amplification might explain drug sensitivity in this setting.

We also assessed the possibility that KGDs could be identified that were associated with specific subtypes of cancer. We, and others, have previously used RNAi data to identify KGDs associated with distinct breast cancer subtypes ([@bib10], [@bib50]). To illustrate the utility of the expanded data set described here, we used MP tests to identify KGDs associated with the clear cell subtype of ovarian cancer (OCC). We found three kinases (*CAMK2N1*, *GRK2*, and *MAP3K9*) to be KGDs in OCC models, compared to other ovarian cancer histologies such as serous ovarian cancer ([Figure S2](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc2){ref-type="supplementary-material"}F).

Candidate KGDs Associated with Driver Gene Alterations {#sec2.3}
------------------------------------------------------

By integrating the siRNA data with exome sequencing ([@bib23]) and copy number profiling data ([@bib4]), we identified KGDs associated with mutations in each of 200 candidate cancer driver genes (see [Supplemental Information](#app3){ref-type="sec"}; [Table S1](#mmc2){ref-type="supplementary-material"}G). We identified 4,247 putative dependencies associated with driver gene mutations (uncorrected MP test p ≤ 0.05; [Table S1](#mmc2){ref-type="supplementary-material"}H). As the large number of tests performed using these 200 driver genes prohibited correction for multiple hypothesis testing, we focused our subsequent analysis on 21 key cancer driver genes (12 tumor suppressor genes and nine oncogenes; [@bib25], [@bib71]) ([Figure 3](#fig3){ref-type="fig"}A) mutated in at least seven tumor cell lines in our panel. This identified 211 KGDs at an FDR of 0.5 ([Table S1](#mmc2){ref-type="supplementary-material"}I) that could form the basis for subsequent validation experiments.

This approach reconfirmed the well-established *ERBB2* oncogene addiction in models of breast cancer, but also established *ERBB2* addiction/KGD in models of esophageal cancer ([Figures 3](#fig3){ref-type="fig"}B and 3C), where *ERBB2* is recurrently amplified/overexpressed in 20% of tumors ([@bib1]). This suggested that this particular genetic dependency was relatively independent of the underlying histotype. *ERBB2* amplification was also associated with dependency upon other members of the ERBB2 signaling network including the ERBB2 binding partner ERBB3 (p = 2 × 10^−3^), JAK2 (p = 1 × 10^−2^), and the downstream effector of ERBB2, PIK3CA (p = 4 × 10^−3^; [Figure 3](#fig3){ref-type="fig"}D). We found other KGDs associated with *ERBB2* amplification, including a strong dependency upon the stress response kinase MEK3 (*MAP2K3,* p = 4 × 10^−4^; [Figure 3](#fig3){ref-type="fig"}D) ([@bib20]) and *PIP5K1A* (p = 2 × 10^−5^), a kinase involved in inositol phosphate metabolism ([@bib45]).

We assessed the possibility that some KGDs associated with cancer driver gene mutations might be private to or more profound in particular histotypes. For example, *BRAF* p.V600E mutant melanomas are extremely sensitive to BRAF inhibition, whereas colorectal cancers with the same mutation show little response ([@bib55]). We used a similar analysis as above to identify KGDs associated with driver gene mutations within particular histotypes and identified 943 KGDs ([Tables S1](#mmc2){ref-type="supplementary-material"}J and S1K), compared to 211 in the prior analysis that combined all histotypes. Together, these 1,154 candidate dependencies could inform the design of subsequent validation studies. As an example of this, we selected for validation one of the KGDs associated with *RB1* mutation in osteosarcoma ([@bib38]), DYRK1A (p = 6.8 × 10^−3^; [Figure S3](#mmc1){ref-type="supplementary-material"}A), a component of the DREAM complex ([@bib59]) previously identified as a protein interaction partner of RB1 ([@bib69]). To confirm the dependency of *RB1* null osteosarcoma models upon *DYRK1A*, we selected 14 osteosarcoma models and characterized these according to their *RB1* mutation and protein expression status and established that multiple distinct *DYRK1A* siRNAs could replicate the *RB1* selectivity observed in the initial screen as well as eliciting *DYRK1A* silencing ([Figure S3](#mmc1){ref-type="supplementary-material"}). These results suggest that *DYRK1A* might represent a valid genetic dependency in *RB1* defective osteosarcoma cells.

We also noted from our analysis of the siRNA data that some genetic dependencies associated with cancer driver gene mutations were observed independently in multiple histotypes. These included KGDs associated with *ERBB2* amplification in breast and esophageal cancer models (e.g., *ERBB2* p = 7.9 × 10^−5^ \[breast\] and p = 9.2 × 10^−3^ \[esophageal\] and *MAP2K3* p = 3.3 × 10^−2^ \[breast\] and p = 4.4 × 10^−3^ \[esophageal\]; [Figure S4](#mmc1){ref-type="supplementary-material"}A), but also a dependency upon the microtubule associated serine/threonine kinase *MAST1* in *CCND1* amplified breast or esophageal cancer models (p = 1.1 × 10^−2^ \[breast\] and p = 1.3 × 10^−2^ \[esophageal\]; [Figure S3](#mmc1){ref-type="supplementary-material"}B). Likewise, a KGD upon Citron Rho-interacting kinase *(CIT)*, a regulator of cytokinesis ([@bib48]) was also seen in *CCND1* amplified breast or esophageal cancer models (p = 2. × 10^−3^ \[breast\], p = 2.6 × 10^−3^ \[esophageal\]; [Figure 3](#fig3){ref-type="fig"}E). In both osteosarcoma (p = 1.4 × 10^−3^) and lung cancer models (p = 3.5 × 10^−2^; [Figure S1](#mmc1){ref-type="supplementary-material"}C), we identified an association between mutation/deletion of *CDKN2A* and dependency upon the cyclin dependent kinase gene *CDK11A*, which encodes a CDKN2A interacting protein ([@bib69]). In total, we identified 63 kinase dependencies associated with driver gene mutation status that were observed independently in more than one histotype ([Table S1](#mmc2){ref-type="supplementary-material"}K).

Integrating Data on Protein-Protein and Regulatory Interactions Facilitates the Interpretation of Genetic Dependencies {#sec2.4}
----------------------------------------------------------------------------------------------------------------------

The set of KGDs associated with cancer driver gene alterations can be used to frame testable hypotheses, such as "mutation in gene *A* drives dependency upon a gene *B*." However, without further information, there are a number of potential mechanistic explanations for each genetic dependency. In model organisms, the problem of interpreting such dependencies has been addressed by integrating information from protein-protein ([@bib8]) and kinase-substrate interaction databases ([@bib22]). To facilitate a mechanistic understanding of KGDs and to provide additional guidance for the design of subsequent experiments, we annotated our list of KGDs according to whether they involved known protein-protein interactions ([@bib13], [@bib19]), known kinase-substrate relationships ([@bib42]), or known regulatory relationships ([@bib12]) between the driver gene and the identified dependency (see [Experimental Procedures](#sec4){ref-type="sec"}). Doing this, we found 113 KGDs involved pairs of genes with a previously reported functional relationship between the mutated driver gene and kinase target ([Tables S1](#mmc2){ref-type="supplementary-material"}I and S1K). For example, mutation/amplification of *EGFR* in lung cancer cell lines was associated with an increased dependency upon FES (p = 3 × 10^−2^; [Figure 3](#fig3){ref-type="fig"}F), previously identified as an EGFR binding partner ([@bib36]). Similarly, in esophageal cancer models, we identified a significant association between mutation of the chromatin remodeling factor gene *SMARCA4* and dependency upon the bromodomain protein BRD4 (p = 6 × 10^−3^; [Figure 3](#fig3){ref-type="fig"}F), previously identified as a protein interaction partner of SMARCA4 ([@bib57]). Among the dependencies associated with a kinase-substrate interaction, we found that mutation of *STK11* (*LKB1*) in ovarian cancer models was associated with an increased dependency upon *MARK2* (p = 2 × 10^−3^; [Figure 3](#fig3){ref-type="fig"}G), an LKB1 substrate ([@bib44]). Similarly, we found that *MYC* (*cMYC*) amplified esophageal models had an increased dependency upon *MAPK1* (ERK-2, p = 1.2 × 10^−2^; [Figure 3](#fig3){ref-type="fig"}G), which is known to phosphorylate and stabilize the cMYC protein ([@bib62]). We also identified a series of dependencies between cancer driver genes and their transcriptional targets, the majority of which focused upon *MYC*. In lung cancer models, we found that *MYC* amplification was associated with an increased dependency upon *CDKL5* (5.6 × 10^−3^; [Figure 3](#fig3){ref-type="fig"}H), a gene whose expression is regulated by *MYC*. Similarly, in esophageal models, we found *MYC* amplification to be associated with an increased dependency upon the *MYC* transcriptional target *PRKCH* ([@bib74]) (p = 6.7 × 10^−3^; [Figure 3](#fig3){ref-type="fig"}H).

For KGDs where a direct relationship between the driver gene and the kinase was not known, we used a simple information-flow type analysis to identify the shortest known molecular paths between driver gene and the kinase dependency ([Tables S1](#mmc2){ref-type="supplementary-material"}I and S1K). For example, one of the strongest dependencies identified across all histotypes was between *STK11* and *SRP72* ([Figure S4](#mmc1){ref-type="supplementary-material"}C). We found no evidence of a direct relationship between the two genes, but found that *STK11* has been shown to regulate the expression of *MYC* ([@bib53]), which in turn has been shown to regulate *SRP72* ([@bib74]), suggesting a putative path linking the driver gene and the kinase dependency. In esophageal cancer models, we found that *ERBB2* amplification is associated with *MASTL* ([@bib70]) and *NEK9* ([@bib5]) KGDs ([Figure 3](#fig3){ref-type="fig"}I). We found no direct link between ERBB2 and either of these kinases, but both are CDK1 substrates and CDK1 itself is an ERBB2 substrate. In this instance, all members of the path (*ERBB2*/*CDK1*/*NEK9*/*MASTL*) were identified as *ERBB2* dependencies. In total, 163 dependencies not supported by a direct link could be reached by adding one intermediate connection (e.g., CDK1 is an intermediate connection between ERBB2 and NEK9).

Pathway and Network Level KGDs {#sec2.5}
------------------------------

Work in model organisms has shown that a genetic mutation often results in an increased dependency on not just one gene, but multiple genes involved in a specific pathway or complex ([@bib16], [@bib39], [@bib58]). To explore the utility of this concept in interpreting our KGD data, we mapped the nominally significant KGDs (p ≤ 0.05) identified for each cancer driver gene across all histotypes onto the high-confidence STRING functional interaction network ([@bib24]) (see [Experimental Procedures](#sec4){ref-type="sec"}). For 11 of the 21 driver genes analyzed (*KRAS*, *ERBB2*, *CCND1*, *PIK3CA*, *SMAD4*, *NOTCH2*, *ARID1A*, *NF1*, *FBXW7*, *MAP2K4*, and *RB1*), we found that the dependencies associated with each driver gene were significantly more connected on the STRING interaction network than would be expected by chance (see [Experimental Procedures](#sec4){ref-type="sec"}; [Figure S5](#mmc1){ref-type="supplementary-material"}; [Table S1](#mmc2){ref-type="supplementary-material"}L). This suggested that these 11 driver genes might induce dependencies not just on individual genes, but on functional subnetworks. For two of these networks, we added known protein-protein and kinase-substrate interaction data to aid their interpretation. In the case of the network associated with *ERBB2* amplification, this suggested that *ERBB2* amplification might induce dependencies on direct binding partners and substrates of ERBB2 (JAK2, ERBB3, and PIK3CA), but also a network of genes involved in MAPK signaling (e.g., *MAP2K3*, *MAP3K4*, and *MAP3K2*) and inositol phosphate metabolism (including *PIP5K1A*, *PIK3CA*, and *PIK3CD*) ([Figure 4](#fig4){ref-type="fig"}A). Similarly, we found significantly more functional interactions among the kinases identified as dependencies associated with mutation of the tumor suppressor *SMAD4*, a member of the TGF-β pathway that is frequently mutated or homozygously deleted in colorectal ([@bib66]), pancreatic ([@bib32]), and esophageal ([@bib21]) cancers ([Figure 4](#fig4){ref-type="fig"}B). The integrated network we constructed from *SMAD4* KGDs revealed that *AKT1* and a number of its substrates (*FGR*, *MAP3K3*, *PIKFYVE*, *CHEK1*, and *WEE1*) were *SMAD4* mutation associated KGDs. Consistent with this, loss of *SMAD4* has been shown to be associated with increased AKT activation in colorectal and pancreatic tumor cell lines ([@bib14], [@bib76]). Furthermore, a recent large-scale drug screen identified *SMAD4* as the only driver gene significantly associated with sensitivity to A-443654, a pan-AKT inhibitor ([@bib26]). In addition to *AKT1* and its substrates, we found a densely connected group of kinases that regulate the mitotic cell cycle in the *SMAD4* dependency network ([Figure 4](#fig4){ref-type="fig"}B), suggesting that *SMAD4* mutant tumor cell lines may have an increased sensitivity to perturbation of this process. To test this hypothesis, we analyzed a compendium of drug sensitivity profiles ([@bib26]) and found that *SMAD4* mutant cell lines have increased sensitivity to the Aurora Kinase inhibitor VX-680 ([@bib33]) (p = 4 × 10^−3^; [Figure 4](#fig4){ref-type="fig"}C). Furthermore, we found that *SMAD4* mutant cell lines also exhibited an increased sensitivity to the mitotic inhibitors paclitaxel (p = 8.3 × 10^−5^) and epothilone B (p = 3 × 10^−3^; [Figure 4](#fig4){ref-type="fig"}C), suggesting a general sensitivity to drugs that target the mitotic checkpoint.

We present the functional interaction networks for the dependencies associated with each driver gene in [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}L. In addition to aiding the interpretation of dependencies, these subnetworks may be useful in alleviating some of the problems associated with false-positive effects in high-throughput genetic screens. Although there is a possibility of any given dependency being the result of off-target siRNA effects ([@bib35]), the likelihood of an entire pathway being identified through off-target effects is likely to be much lower.

In the examples described above, we used the siRNA data to identify KGDs associated with defects in individual driver genes. Although there are hundreds of reported driver genes in cancer, some of these can be grouped into a small number of recurrently altered pathways ([@bib27]). Furthermore, it is possible that mutation in any member of such a pathway might have similar phenotypic effects. With this in mind, we considered whether we could identify candidate "pathway level" dependencies by grouping tumor cell lines according to mutations in any one of a set of driver genes belonging to the same pathway or complex. We obtained a previously curated list of pathways associated with driver gene mutations ([@bib27]) and manually updated this using literature information on well-established pathways (e.g., homologous recombination). For each pathway, tumor cell lines were grouped using a logical OR argument, i.e., if a cell line possessed a functional mutation of any gene member of the pathway then that cell line was considered mutated in that pathway. This resulted in a set of 15 pathway groupings ([Table S1](#mmc2){ref-type="supplementary-material"}M) that were perturbed in at least seven tumor cell lines. Associating pathway mutations with KGDs was then performed in the same way as for individual genes using the MP test approach. This resulted in the identification of an additional 338 dependencies across all histotypes ([Table S1](#mmc2){ref-type="supplementary-material"}N) and 748 histotype-specific dependencies ([Table S1](#mmc2){ref-type="supplementary-material"}O).

As with individual driver genes, we found that the mutation of pathways was often associated with dependencies that were densely connected on the STRING functional interaction network. Indeed, using the dependencies identified across all histotypes, we found that nine of the 15 pathways (HR, PRC2, PI3K signaling, Cell Cycle Oncogenes, Cell Cycle Merged, TOR Signaling, MAPK Signaling, TGF B Signaling, and RAS/RAF Signaling) were associated with dependencies that were more functionally connected than would be expected by chance. This suggested that mutation of one pathway may induce dependency on a second pathway, consistent with observations from yeast where it has been shown genetic dependencies can often be best explained as occurring between pairs of pathways ([@bib39]). The dependency graphs associated with each pathway are presented in [Figure S5](#mmc1){ref-type="supplementary-material"}.

In some instances, the association between a pathway and kinase siRNA had a predictive value no greater than the association with an individual member of the pathway. For example, alteration in the mTOR signaling pathway (mutation in *TSC1* OR *TSC2* OR *STK11*) was associated with an increased dependency upon the signal recognition particle *SRP72* gene (rho = −0.40), but mutation of *STK11* alone better explained the relative sensitivity of mutant and non-mutant cell lines in this regard (rho = −0.44). We therefore filtered these associations to identify 175 across-histotype ([Table S1](#mmc2){ref-type="supplementary-material"}N) and 608 histotype-specific pathway dependencies where the pathway was a better predictor of dependency than any one individual gene ([Table S1](#mmc2){ref-type="supplementary-material"}O). One example of a pathway dependency involved loss-of-function mutations in the genes encoding components of the SWI/SNF complex, mutated in ∼20% of all human cancers. By grouping all tumor cell lines that had a loss-of-function mutation or homozygous deletion of any member of the SWI/SNF complex (including the genes *ARID1A*, *SMARCA1*, *SMARCA4*, *ARID2*, *ARID1B*, and *PBRM1*) and then carrying out MP tests on the siRNA data as before, we identified ten KGDs including *TWF2* ([Figure 5](#fig5){ref-type="fig"}A), a gene encoding a protein that affects the stability of the actin cytoskeleton through interaction with G-actin ([@bib54]). Further dependencies were identified for this complex within specific histotypes including the uridine-cytidine kinase gene *UCK2* ([@bib68]) in ovarian cancer models ([Figure 5](#fig5){ref-type="fig"}B) and the death-associated protein kinase gene *DAPK1* in esophageal cancer models ([Figure 5](#fig5){ref-type="fig"}C).

We also investigated MAPK gene alterations (including *RAS* gene or *BRAF* mutations) as a pathway and found a *CDK6* KGD ([Figure 5](#fig5){ref-type="fig"}D). The dependency of *KRAS* mutant tumor cell lines upon CDK6 was readily apparent (rho = −0.38), but was stronger when *KRAS*, *HRAS*, *NRAS*, or *BRAF* mutant tumor cell line models were combined as a group (rho = −0.43). CDKs, including CDK6, have been identified by a number of groups as putative non-oncogene addictions for *KRAS* mutant cancers ([@bib3], [@bib56]). Our results suggest that *CDK6* might be a non-oncogene addiction not just for *KRAS* mutant models, but also for cell lines with any one of a variety of MAPK activating mutations (*NRAS*, *HRAS*, and *BRAF*). We tested this hypothesis using published drug screening results for a CDK4/6 inhibitor (PD0332991) in 628 cell lines ([@bib26]) and found a significant association between mutation of the MAPK pathway and sensitivity to this inhibitor (p = 2.5 × 10^−3^, Mann-Whitney U \[MW U\]-test). None of the individual members of this pathway showed as strong an association with this inhibitor (KRAS p = 1.9 × 10^−1^, HRAS p = 5.8 × 10^−2^, NRAS p = 1.7 × 10^−2^, BRAF p = 2.8 × 10^−2^, and MW U-test).

Discussion {#sec3}
==========

A key challenge in the study of cancer biology is to understand how driver mutations alter the cellular state to promote tumor progression and how these altered states may be exploited in the development of targeted therapeutic approaches to the disease ([@bib73]). Here, we have used siRNA screening to quantitatively estimate the kinase requirements of tumor cell lines in an attempt to understand better the genetic dependencies present. By integrating our siRNA data with molecular and histotype classifications, we have identified KGDs associated with particular cancer histologies or the presence of particular driver gene mutations. By integrating the KGD data with additional sources of annotation, such as protein-protein interaction data, we have tried to exemplify how testable hypotheses can be framed to explain the associations between a biomarker, such as a driver gene mutation, and a kinase dependency. Our aim in providing this data and illustrating its potential utility is to present starting points for further work.

As with any large functional data set, it is important to point out where elements of the technology used might influence the interpretation of the data. In general, siRNA mediated gene silencing is transient, when compared to, for example, short hairpin (sh)RNA mediated RNAi. With this in mind, we used a relatively short cell culture period between transfection and cell viability assessment (a 4 to 7 day period). Nevertheless, we cannot predict whether longer-term cell culture or longer-term gene silencing might result in a somewhat different profile of genetic dependencies. Furthermore, we used an ATP-based assay of cell viability in the screens. Some modes of cell inhibition exist that might have been missed using this method. As with any high-throughput technique, siRNA screens also have inherent false-positive and false-negative effects. Addressing false positives is especially important given the well-documented off-target effects associated with RNAi reagents ([@bib35]). Consequently, we recommend that subsequent work that builds on the dependencies we have identified encapsulates some form of orthogonal validation. Individual siRNAs designed to target a gene (as we have shown in the case of *DYRK1A* dependency in *RB1* null cell lines) or small molecule inhibitors (as we have shown for the FGFR sensitivity of osteosarcoma cell lines) might be used as a form of validation. Alternatively, methods such as CRISPR-Cas9 mediated gene targeting ([@bib61]) might be appropriate. We also note that like all genetic screen data sets, the negative predictive value of our data (i.e., the prediction that a particular genetic dependency does not exist) might be somewhat limited, given the transient and sometimes incomplete nature of gene silencing by siRNA.

In carrying out functional screens in cancer cell lines, we have tried to use some of the lessons learned from studies in model organisms to aid the interpretation of our identified dependencies. For example, integrating protein-protein interaction data with functional data ([Figure 5](#fig5){ref-type="fig"}) was an approach pioneered in the study of yeast genetic interaction screens ([@bib8], [@bib39]). Here, we have integrated this type of data to help frame testable hypotheses relating to the observed dependencies. A more sophisticated level of protein-protein interaction data for human tumor cell lines ([@bib41]) will undoubtedly enhance our ability to understand genetic dependencies. Similarly the availability of phosphoproteomic data for the cell lines in our panel may facilitate a more mechanistic reconstruction of the signaling networks active in each cell line. A number of approaches (e.g., [@bib63], [@bib65]) have been developed to integrate siRNA or small molecule perturbations with time-course phosphoproteomics data sets to reconstruct signaling networks. Currently phosphoproteomic data for cancer cell line panels are relatively limited (e.g., [@bib11], [@bib18]), but as the overlap of cell lines covered by these phosphoproteomic resources and our siRNA resource increases there will be opportunities for the development of further integrative modeling approaches. Similarly, the increased availability of protein expression data sets (e.g., [@bib43], [@bib52]) may provide further opportunities for the development of additional integrative approaches.

Finally, to make our resource as useful to the community as possible, we have made all of the data described in this manuscript available (<https://cansar.icr.ac.uk/>), alongside the computational scripts used to integrate data (<https://github.com/GeneFunctionTeam/cell_line_functional_annotation>).

Experimental Procedures {#sec4}
=======================

siRNA and Small Molecule Screening {#sec4.1}
----------------------------------

Cell lines were transfected with a plate-arrayed siRNA library targeting 714 kinases and kinase-related genes (Dharmacon SMARTpools). Positive control (siPLK1) and multiple negative controls (siCON1 and siCON2; Dharmacon, catalog numbers D-001210-01-20 and D-001206-14-20) and AllStar (QIAGEN, catalog number 1027281) were included on every plate. 20 breast cancer models were screened in a 96-well-plate format while the remaining cell lines were screened in a 384-well-plate format ([Table S1](#mmc2){ref-type="supplementary-material"}A). All screens were performed in triplicate. Cell viability was estimated as cells reached 70% confluency (normally 4--7 days after transfection) using a CellTiter-Glo assay (Promega). Data processing and quality control was performed using the cellHTS2 R package ([@bib9]). Further details, including small molecule sensitivity testing, are provided in the [Supplemental Information](#app3){ref-type="sec"}.

Association Testing {#sec4.2}
-------------------

To identify associations between specific features (histotype or driver gene mutation) and sensitivity to specific siRNAs, a one-sided MP test was used. For each siRNA, we compared the observed difference between the median *Z* score of the interest group and the median *Z* score of the "other" group to that expected based on random permutation. There were one million random samples that were created with the same sample sizes as the interest and other groups and the difference in the medians of the two groups calculated, allowing an empirically determined p value to be calculated. Correction for multiple testing was performed using the Benjamini and Hochberg FDR ([@bib6]) and only those at an FDR of 50% are reported. For all small molecule association tests, we used a one-sided MW U test on area under the dose response curve values.

Data Access {#sec4.3}
-----------

All siRNA *Z* score data can be found in [Table S1](#mmc2){ref-type="supplementary-material"}B and also at <https://cansar.icr.ac.uk/>.

Data Integration {#sec4.4}
----------------

Data from HINT ([@bib19]), BioGRID version 3.4.128 ([@bib13]), and KEA protein- protein interaction databases were used ([@bib42]). Kinase-substrate interactions were obtained from KEA ([@bib42]), PhosphoSitePlus ([@bib34]) and ([@bib15]). High confidence (combined score \>0.7) functional interactions were obtained from the STRING database (Version 9.1; [@bib24]). Gene expression relationships were obtained from Pathway Commons ([@bib12]). The shortest_path function in NetworkX ([@bib31]) was also used. Further details are provided in the [Supplemental Information](#app3){ref-type="sec"}.
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Accession Numbers {#app1}
=================

The accession number for the exome sequencing data of 11 ovarian cancer cell lines reported in this study is ENA: PRJEB9639.

Supplemental Information {#app3}
========================

Document S1. Supplemental Experimental Procedures and Figures S1--S5Table S1. Data Sets Used in the Study and Analysis Result Tables, Related to Figure 1AThe sheet named "explanation of the tables" details the contents of individual worksheets.Table S1A shows an overview of 136 cell lines screened, screening conditions, and quality control data for their associated siRNA screens.Table S1B shows high quality siRNA screen results, *Z* score data for 714 genes in 117 cell lines. Sorting each column in ascending order will reveal the cell lines most sensitive to each siRNA.Table S1C shows tests of correlation between expression of kinase expression and dependency on the same kinases. The columns contain the identifier of each kinase, the statistical significance of the correlation, and the Spearman correlation coefficient.Table S1D shows the dependencies associated with specific histotypes.Table S1E shows the AUC values for two FGFR inhibitors in a panel of cell lines and known FGFR1 and FGFR2 amplification status of cell lines.Table S1F shows the dependencies associated with the ovarian clear cell histotype.Table S1G shows the mutation status for putative driver genes included in the association tests.Table S1H shows the dependencies associated with the alteration of 200 putative driver genes across all histologies. Only those dependencies with an uncorrected median permutation test p of 0.05 or lower are reported. In addition to the p values derived from median permutation testing, we provide those obtained from MW (Wilcox) and Spearman's correlation. The Spearman's rank correlation provides a reasonable proxy for the separation between groups, strong negative values indicate that the mutant cell lines are more sensitive to the target than the non-mutant group.Table S1I shows dependencies associated with the alteration of 21 driver genes across all histologies. Only those dependencies with an FDR of 0.5 or less are reported (explanation as for Table S1H). For ease, these dependencies have been annotated according to whether the driver and target physically interact (according to HINT, BioGRID, or high-confidence String interactions) or have a kinase-substrate relationship (according to KEA). The shared pathways between driver and target from GSEA are also annotated. Finally the "Functional Relationship" column is set to 1 if the driver gene and target share a physical interaction according to any of the three databases or a kinase-substrate interaction.Table S1J shows dependencies associated with the alteration of 200 putative driver genes within specific histologies. Only those dependencies with an uncorrected median permutation test p value of 0.05 or lower are reported (explanation as for Table S1H).Table S1K shows dependencies associated with the alteration of 21 driver genes within specific histologies (BREAST, OSTEOSARCOMA, LUNG, OESOPHAGUS, OVARIAN) (explanation as for Table S1H).Table S1L shows the network edges for kinase dependency networks associated with driver gene mutation status.Table S1M shows the pathway definitions used for the identification of dependencies associated with pathway mutation.Table S1N shows dependencies associated with the alteration of specific pathways across all histologies. MoreSignificantThanGenes indicates whether the pathway is a better predictor of sensitivity than each of the individual genes in the pathway. BestIndividualGene indicates the individual member of the pathway that is the best predictor of sensitivity to the siRNA and BestIndividualR gives the Spearman's correlation associated with that gene.Table S1O shows dependencies associated with the alteration of specific pathways within specific histologies (BREAST, OSTEOSARCOMA, LUNG, OESOPHAGUS, OVARIAN) (explanation as for Table S1N).Document S2. Article plus Supplemental Information
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![Screening Overview\
(A) Schematic of siRNA screening, data processing, and genomic data integration.\
(B) Piechart illustrating histotypes for 117 cell lines that passed QC (CNS).\
(C) Frequency plot depicting the number of cell lines in which each kinase siRNA caused a significant growth defect (*Z* ≤ −2).\
(D) Clustered heatmap summarizing the KGDs of 117 cell lines. The average linkage hierarchical clustering was used with Pearson's correlation as the similarity metric. Only the 20% most variable siRNA *Z* scores were used for the calculation of correlations. The histotype of each cell line is indicated by the color blocks to the left of the heatmap and corresponds to the scheme shown in (B).](gr1){#fig1}

![Kinase Dependencies Associated with Histotypes\
(A) Radar plot summarizing the KGDs associated with the osteosarcoma histotype. The concentric circles indicate the statistical significance and the depth of color indicates the separation of *Z* scores between the osteosarcoma histotype and the non-osteosarcoma group of cell lines. A set of six kinases annotated as involved in skeletal system morphogenesis in the Gene Ontology are annotated with asterisks.\
(B) Heatmap of KGDs enriched in osteosarcoma cell lines are shown as a heatmap representing siRNA *Z* scores. The asterisks indicate kinases involved in skeletal system morphogenesis as in (A).\
(C and D) Box plots of area under curve (AUC) estimates for 58 cell lines exposed to the FGFR inhibitor AZD4547 (C) and PD173074 (D) at eight different concentrations. *FGFR1* and *FGFR2*-amplified cell lines are indicated with black and green circles, respectively. The non-tumor epithelial cell lines MCF10A and MCF12A are indicated with gray arrows.\
(E) Box plot of AUC estimates for a panel of cell lines exposed to the FGFR inhibitor PD173074 ([@bib26]).\
In each box plot (C--E), the top and bottom of the box represents the third and first quartiles and the box band represents the median (second quartile); whiskers extend to 1.5 times the interquartile distance from the box. See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![KGDs Associated with Cancer Driver Mutations\
(A) Bar chart indicating the frequency of driver gene alterations observed in the cell line panel. The colored segments in each bar indicate the histotypes in which alterations were detected.\
(B) Radar plot summarizing the KGDs associated with *ERBB2* amplification (the scheme as per [Figure 2](#fig2){ref-type="fig"}A).\
(C) Box plot showing the ERBB2 *Z* scores for cell lines grouped according to *ERBB2* amplification status. The colors indicate cell line histotypes as in (A).\
(D) Box plots showing additional KGDs associated with *ERBB2* amplification.\
(E) Box plots summarizing *CCND1* KGDs upon *CIT*.\
(F) Examples of KGDs that are supported by protein-protein interactions.\
(G) Examples of KGDs that are supported by kinase-substrate relationships.\
(H) Examples of KGDs that are supported by gene regulatory relationships.\
(I) Examples of KGDs associated with *ERBB2* amplification status in esophageal cancer models supported by kinase-substrate relationships that form a shortest path between the mutated driver gene and kinases.\
In each box plot (C--I), the top and bottom of the box represents the third and first quartiles and the box band represents the median (second quartile); whiskers extend to 1.5 times the interquartile distance from the box. See also [Figures S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"}I and S1K.](gr3){#fig3}

![Driver Gene KGDs and Functional Interaction Networks\
(A) Functional interaction network showing interactions between *ERBB2* amplification-associated KGDs. The nodes correspond to kinases that are identified as KGDs in *ERBB2* amplified cell lines. The nodes are scaled to indicate the significance of the KGD association p value. The blue edges correspond to experimentally determined protein-protein interactions, the pink arrows indicate the direction of experimentally determined kinase-substrate interactions, and the gray edges reflect high-confidence STRING functional interactions. Only KGDs that interact with at least one other *ERBB2* dependency are shown.\
(B) Functional interaction network showing interactions among KGDs identified in *SMAD4* mutated cancer cell lines. Details as for *ERBB2* network in (A).\
(C) Box plot showing AUC values of a panel of cell lines exposed to compounds targeting microtubules (paclitaxel and epothilone B) or Aurora Kinases (VX680) and classified into *SMAD4* mutant or wild-type groups. The top and bottom of the box represents the third and first quartiles and the box band represents the median (second quartile); whiskers extend to 1.5 times the interquartile distance from the box.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc2){ref-type="supplementary-material"}L.](gr4){#fig4}

![Pathway Mutations Associated with KGDs\
(A) Heatmap showing increased dependency on *TWF2* in cell lines with loss-of-function mutations in members of the SWI-SNF complex.\
(B) Heatmap showing increased dependency on *UCK2* in ovarian cancer cell lines with loss-of-function mutations in members of the SWI-SNF complex.\
(C) Heatmap showing increased dependency on *DAPK1* in esophageal cancer cell lines with loss-of-function mutations in members of the SWI-SNF complex.\
(D) Heatmap showing increased dependency upon *CDK6* in cell lines bearing mutations in *KRAS*, *HRAS*, *NRAS*, or *BRAF*.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"}M--S1O.](gr5){#fig5}
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